Assembly Biosciences (ASMB) is a clinical-stage antiviral company with no approved products and a cumulative accumulated deficit of $841.1 million as of March 31, 2026. Under a liquidation lens, the recovery posture is marginally positive but thin, driven almost entirely by liquid financial assets. Total assets of $235.5 million are composed predominantly of cash and cash equivalents ($31.1 million) and available-for-sale marketable securities ($195.5 million), both of which carry near-100% recovery under liquidation assumptions. PP&E is de minimis at $214 thousand net book value. Operating lease ROU assets of $2.4 million receive a haircut to zero under liquidation. Intangibles and pipeline value are assigned zero. On the liability side, total liabilities of $36.9 million are held at face value. The dominant liability is deferred revenue (ContractWithCustomerLiabilityCurrent) of $29.1 million, representing unearned collaboration payments from Gilead. This deferred revenue obligation does not extinguish on wind-up — any remaining performance obligations would likely require cash settlement or reimbursement to Gilead, making it a hard face-value claim. Operating lease liabilities total $2.5 million ($0.6M current, $1.9M non-current), which also survive liquidation at face value per ASC 842. Accrued liabilities and accounts payable add approximately $4.1 million. Estimated gross liquidation value of assets (cash at 100%, securities at 100%, AR at 92%, prepaid/other minimal recovery) approximates $228–229 million. Net equity recovery after settling $36.9 million in total liabilities at face would be approximately $191–192 million, or roughly $12.00 per share on ~15.9 million shares outstanding, before wind-down costs and contingent obligations. This is consistent with MFFAIS CLV figures in the negative range only if wind-down costs, severance, and lease termination penalties are layered in. The key liquidation risk is the $29.1 million Gilead deferred revenue: if the Gilead Collaboration Agreement requires refund or clawback upon termination, this is the single largest claim against the liquid asset pool. The filing discloses that Gilead declined to exercise its option on 4334 in March 2026 and exercised its option on the HPI program in December 2025 ($35.0 million payment received). Cash burn was $22.1 million operating outflow in Q1 2026; the $226.6 million liquid pool supports approximately 10 quarters at current burn absent additional financing. The filing does not separately tag the fair value hierarchy breakdown of marketable securities in XBRL, though MD&A confirms these are investment-grade AFS securities. Ownership change event occurred in August 2025 (Gilead equity purchase), which triggered Section 382 NOL limitations; NOLs carry no recovery value under liquidation.
▼ Community Notes